REMEDENT USA INC/AZ
10SB12B/A, EX-10.1(I), 2000-09-15
DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES
Previous: REMEDENT USA INC/AZ, 10SB12B/A, 2000-09-15
Next: REMEDENT USA INC/AZ, 10SB12B/A, EX-10.8, 2000-09-15





                         ADDENDUM TO MARKETING AGREEMENT

         This  Addendum  is  effective  as of  November  5,  1998  and  shall be
considered a binding  attachment to the October 5, 1996  Marketing  Agreement by
and among Remedent USA, Inc. and Jean Louis Vrignaud.

         In witness whereof, the parties agree as follows:

         1. Both parties agree that expending a budget of US $1.5 million during
the first three years is not feasible.  Item 2.1 of the  Marketing  Agreement is
hereby amended to state that the  promotional  budget should be  proportional to
the number of stores in which distribution is achieved, and no minimum amount is
required to maintain the validity of the Marketing Agreement. Remedent agrees to
advertise the product once distribution justifies such advertising.

         2. Both  parties  agree that long term  testing of the  product  with a
large  number of Dentists  who monitor  their  patients  is  significantly  more
valuable than clinical tests as described in 2.2 of the Marketing Agreement, and
substantially  less expensive.  The expenditure of $150,000 for clinical testing
is therefore no longer a requirement of the Marketing Agreement. Remedent agrees
however  to  aggressively   continue  to  promote  the  product  to  the  dental
professional  community  in order to gain the  maximum  amount  of  professional
dental endorsement.

         As a shareholder of Remedent USA,  Inc.,  Vrignaud feels that the above
modifications to the Marketing  Agreement dated October 5, 1996, are in the best
interest of the company and himself as a shareholder.

BY                                                       Date
   -------------------------------------------------           ----------------
         Jean Louis Vrignaud

BY                                                       Date
  --------------------------------------------------           ----------------
         Rebecca Inzunza for Remedent USA, Inc.



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission